EXCLUSIVE LICENSE AND ASSET PURCHASE AGREEMENTExclusive License and Asset Purchase Agreement • August 4th, 2017 • Immunogen Inc • Pharmaceutical preparations • New York
THIS EXCLUSIVE LICENSE AND ASSET PURCHASE AGREEMENT (this “Agreement”) is made effective as of May 23, 2017 (the “Effective Date”) by and between Debiopharm International, S.A., a Swiss limited company (“Debiopharm”) having a place of business at Forum “après-demain,” Chemin Messidor 5-7, Case Postale 5911, CH-1002 Lausanne, Switzerland, and ImmunoGen, Inc., a Massachusetts corporation (“ImmunoGen”) having a place of business at 830 Winter Street, Waltham, MA 02451-1477, U.S.A. ImmunoGen and Debiopharm are sometimes each hereinafter referred to as a “Party” and collectively as the “Parties”.
EXCLUSIVE LICENSE AND ASSET PURCHASE AGREEMENT BY AND AMONG 3M COMPANY, 3M INNOVATIVE PROPERTIES COMPANY, AND ADAMIS PHARMACEUTICALS CORPORATION.Exclusive License and Asset Purchase Agreement • August 6th, 2013 • Adamis Pharmaceuticals Corp • Pharmaceutical preparations • Minnesota
THIS AGREEMENT, made this 1st of August 2013, (“Signing Date”) by and among 3M COMPANY and 3M INNOVATIVE PROPERTIES COMPANY ( “3M IPC”) (together, “3M”), Delaware corporations having offices at 3M Center, St. Paul, Minnesota 55144, and ADAMIS PHARMACEUTICALS CORPORATION. a Delaware corporation having its address at 11455 El Camino Real, Suite 310, San Diego, CA 92130 (hereinafter “ADAMIS”). 3M IPC is a wholly owned subsidiary of 3M COMPANY. Hereinafter a reference to “3M” or “ADAMIS” shall include their respective Affiliates where performance would be expected from or required by an Affiliate.
